MarketPR
StockStory, a market research platform, identified AbbVie as the sole S&P 500 constituent with competitive advantages in its latest review, while flagging Starbucks and Zimmer Biomet as names to avoid.
The analysis contrasts the operational resilience of the biopharmaceutical giant with the stagnating trends observed in the coffeehouse and orthopedic sectors.
AbbVie (NYSE:ABBV), which emerged from a 2013 spinoff of Abbott Laboratories' pharmaceutical business, holds a market capitalization of $484.8 billion.
The company develops and markets medications for autoimmune diseases, cancer, and neurological disorders.
Keep reading